REG - RTW Biotech Opp. - Update on Artios Pharma

RTW Biotech OpportunitiesAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250502:nRSB1407Ha&default-theme=true

RNS Number : 1407H  RTW Biotech Opportunities Ltd  02 May 2025

LEI: 549300Q7EXQQH6KF7Z84

2 May 2025

RTW Biotech Opportunities Ltd

Update on Artios Pharma

 

RTW Biotech Opportunities Ltd (the "Company"), the London Stock
Exchange-listed investment company focused on identifying transformative
assets with high growth potential across the life sciences sector, is pleased
to note the announcement by one of its private portfolio companies, Artios
Pharma ("Artios"), of encouraging data in its ongoing Phase 1/2a study of lead
candidate, ART0380.

 

Artios is a private UK-based pharmaceutical company whose mission is to
develop new classes of medicines that exploit DNA damage response (DDR)
pathways with the aim of improving outcomes for patients with hard-to-treat
cancers. The Company first invested in Artios' Series C round in 2021 and
subsequently increased its position significantly when it acquired the assets
of Arix Bioscience in 2024. As at 31 March 2025, Artios represented 5.3% of
the Company's NAV.

 

In an Artios presentation at the American Association for Cancer Research
(AACR) Annual Meeting 2025 in Chicago, ART0380 in combination with low-dose
irinotecan was shown to demonstrate a 50% confirmed overall response rate
(cORR) in patients with Ataxia-Telangiectasia Mutated (ATM)-negative(1) solid
tumors at the recommended Phase 2 dose.

 

With ART0380, Artios is pursuing a differentiated clinical development path by
selectively targeting the protein kinase Ataxia telangiectasia and
Rad3-related (ATR) that plays a key role in the cellular response to
replication stress, a process that can occur via chemotherapy. Artios'
approach exploits replication stress to kill cancer cells through triple
targeting: selecting cancers with high replication stress, inducing further
replication stress with a low dose of irinotecan, and preventing cellular
rescue by inhibiting ATR with ART0380.

 

Rod Wong, CIO of RTW Investments, said, "We are thrilled to see the promising
results from the STELLA Phase 1/2a study of ART0380. The innovative approach
of combining ART0380 with low-dose irinotecan to amplify replication stress is
groundbreaking and validates Artios' unique strategy in targeting DNA damage
response mechanisms. These unprecedented results not only highlight the
potential of ART0380 to significantly improve patient outcomes but also
reinforce our confidence in Artios' leadership in the field of targeted
oncology. We were an early investor in Artios and materially increased our
position through the Arix transaction. We look forward to the continued
development and expansion of this promising therapy."

 

The full text of the announcement can be read at  https://artios.com
(https://www.artios.com/press-release/artios-pharma-reports-differentiated-clinical-activity-in-stella-phase-1-2a-study-for-lead-program-art0380-at-the-american-association-for-cancer-research-aacr-annual-meeting-2025/)
.

Enquiries:

 RTW Investments, LP - Investment Manager               +44 (0)20 7959 6361

 Woody Stileman (Business Development)                  biotechopportunities@rtwfunds.com

 Oliver Kenyon (Business & Corporate Development)

 Krisha McCune (Investor Relations)

 Cadarn Capital - PR & IR Partner

 Lucy Clark (PR)                                        +44 (0)7984 184 461 / lucy@cadarncapital.com

 David Harris (Distribution)                            +44 (0)7368 883 211 / david@cadarncapital.com

 Deutsche Numis - Joint Corporate Broker                +44 (0)20 7260 1000

 Freddie Barnfield

 Nathan Brown

 Euan Brown

 BofA Securities - Joint Corporate Broker               +44 (0)20 7628 1000

 Edward Peel

 Alex Penney

 Altum (Guernsey) Limited                               +44 (0)1481 703 100

 Joanna Duquemin Nicolle

 Sadie Morrison

 

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on
identifying transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/)  for more
information.

 

***********

The information in this announcement may include forward-looking statements,
which are based on the current expectations and projections about future
events, and in certain cases can be identified by the use of terms such as
"may", "will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives thereon) or other
variations thereon or comparable terminology. These forward-looking
statements, as well as those included in any related materials, are subject to
risks, uncertainties and assumptions about the Company and/or its underlying
investments, including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use of financing
proceeds and future capital expenditures and acquisitions. In light of these
risks, uncertainties and assumptions, the events in the forward-looking
statements may not occur.

The information contained in this announcement is given at the date of its
publication (unless otherwise marked). No reliance may be placed for any
purpose whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or fairness.

***********

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDEAKSFEAKSEFA